Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206-3701, USA.
J Biomed Inform. 2014 Apr;48:114-21. doi: 10.1016/j.jbi.2013.12.009. Epub 2013 Dec 18.
Biomedical prediction based on clinical and genome-wide data has become increasingly important in disease diagnosis and classification. To solve the prediction problem in an effective manner for the improvement of clinical care, we develop a novel Artificial Neural Network (ANN) method based on Matrix Pseudo-Inversion (MPI) for use in biomedical applications. The MPI-ANN is constructed as a three-layer (i.e., input, hidden, and output layers) feed-forward neural network, and the weights connecting the hidden and output layers are directly determined based on MPI without a lengthy learning iteration. The LASSO (Least Absolute Shrinkage and Selection Operator) method is also presented for comparative purposes. Single Nucleotide Polymorphism (SNP) simulated data and real breast cancer data are employed to validate the performance of the MPI-ANN method via 5-fold cross validation. Experimental results demonstrate the efficacy of the developed MPI-ANN for disease classification and prediction, in view of the significantly superior accuracy (i.e., the rate of correct predictions), as compared with LASSO. The results based on the real breast cancer data also show that the MPI-ANN has better performance than other machine learning methods (including support vector machine (SVM), logistic regression (LR), and an iterative ANN). In addition, experiments demonstrate that our MPI-ANN could be used for bio-marker selection as well.
基于临床和全基因组数据的生物医学预测在疾病诊断和分类中变得越来越重要。为了解决医学应用中有效的预测问题,以提高临床护理水平,我们开发了一种基于矩阵伪逆(MPI)的新型人工神经网络(ANN)方法。MPI-ANN 被构建为一个具有三个层(即输入层、隐藏层和输出层)的前馈神经网络,并且在没有冗长的学习迭代的情况下,基于 MPI 直接确定连接隐藏层和输出层的权重。还提出了 LASSO(最小绝对收缩和选择算子)方法进行比较。使用单核苷酸多态性(SNP)模拟数据和真实乳腺癌数据通过 5 倍交叉验证来验证 MPI-ANN 方法的性能。实验结果表明,MPI-ANN 对于疾病分类和预测是有效的,因为其具有明显更高的准确性(即正确预测的比率),优于 LASSO。基于真实乳腺癌数据的结果还表明,MPI-ANN 比其他机器学习方法(包括支持向量机(SVM)、逻辑回归(LR)和迭代 ANN)具有更好的性能。此外,实验还表明,我们的 MPI-ANN 可用于生物标志物选择。